miR-100 represses mTOR (mammalian target of rapamycin) signaling and increases sensitivity to the cancer drug everolimus (rapamycin analog RAD001) in cell lines derived from clear cell carcinomas. The gene discussed is MTOR; the disease is clear cell adenocarcinoma.